HONG KONG – Early oral administration of an immune modulator that is normally used for treatment of relapsing multiple sclerosis (MS) significantly reduced brain inflammation and improved the clinical outcomes of acute ischemic stroke (AIS) patients enrolled in a small, early phase pilot study conducted in China.